Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amitex PSE is a combination pharmaceutical product containing the expectorant guaifenesin and the nasal decongestant pseudoephedrine. Formulated as an extended-release tablet, it is indicated for the temporary relief of cough and nasal congestion associated with the common cold, hay fever, or other upper respiratory allergies. Guaifenesin functions as an expectorant by thinning and loosening bronchial secretions, thereby increasing the efficiency of the cough reflex to remove accumulated mucus. Pseudoephedrine is a sympathomimetic amine that acts primarily as an agonist at alpha-adrenergic receptors in the respiratory mucosa, leading to vasoconstriction, reduced tissue hyperemia, and decreased nasal congestion. The product was manufactured by Actavis Totowa but was subject to a voluntary recall in 2008 due to manufacturing practice concerns.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Amitex PSE.